GILD Gilead Sciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GILD

Price (delayed)

$67.03

Market cap

$83.5B

P/E Ratio

14.76

Dividend/share

$3.02

EPS

$4.54

Enterprise value

$102.41B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
GILD's P/E is 77% below its 5-year quarterly average of 65.5 and 16% below its last 4 quarters average of 17.5
The quick ratio has grown by 8% from the previous quarter and by 7% YoY
GILD's EPS is up by 24% year-on-year but it is down by 3.6% since the previous quarter
The company's net income rose by 23% YoY but it fell by 3.6% QoQ
GILD's gross profit is down by 4.7% YoY and by 4.5% QoQ
The gross margin has contracted by 4.2% YoY and by 3.6% from the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: https://www.gilead.com/
Peers: AMGN VRTX ABBV ILMN

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$83.5B
Enterprise value
$102.41B
Valuations
Price to earnings (P/E)
14.76
Price to book (P/B)
3.66
Price to sales (P/S)
3.09
EV/EBIT
13.04
EV/EBITDA
9.71
EV/Sales
3.78
Earnings
Revenue
$27.12B
EBIT
$7.86B
EBITDA
$10.55B
Free cash flow
$7.42B
Per share
EPS
$4.54
Free cash flow per share
$5.95
Book value per share
$18.32
Revenue per share
$21.73
TBVPS
$21.92
Balance sheet
Total assets
$62.13B
Total liabilities
$39.38B
Debt
$24.99B
Equity
$22.83B
Working capital
$4.81B
Liquidity
Debt to equity
1.09
Current ratio
1.43
Quick ratio
1.06
Net debt/EBITDA
1.79
Margins
EBITDA margin
38.9%
Gross margin
76%
Net margin
20.9%
Operating margin
28%
Efficiency
Return on assets
9.1%
Return on equity
26%
Return on invested capital
23.1%
Return on capital employed
15.5%
Return on sales
29%
Dividend
Dividend yield
4.51%
DPS
$3.02
Payout ratio
66.5%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
0.12%
1 week
-0.42%
1 month
-7.68%
1 year
-22.57%
YTD
-17.26%
QTD
-8.49%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$27.12B
Gross profit
$20.62B
Operating income
$7.61B
Net income
$5.67B
Gross margin
76%
Net margin
20.9%
Gilead Sciences's net margin has increased by 24% YoY but it has decreased by 2.3% QoQ
The company's net income rose by 23% YoY but it fell by 3.6% QoQ
The operating income has declined by 8% since the previous quarter but it has grown by 3.8% year-on-year
The operating margin has contracted by 7% from the previous quarter but it has grown by 4.1% YoY

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
GILD P/E details
P/E
14.76
P/B
3.66
P/S
3.09
EV/EBIT
13.04
EV/EBITDA
9.71
EV/Sales
3.78
GILD's P/E is 77% below its 5-year quarterly average of 65.5 and 16% below its last 4 quarters average of 17.5
GILD's EPS is up by 24% year-on-year but it is down by 3.6% since the previous quarter
The stock's price to book (P/B) is 19% less than its last 4 quarters average of 4.5 and 15% less than its 5-year quarterly average of 4.3
Gilead Sciences's equity has increased by 8% YoY and by 2.3% from the previous quarter
GILD's price to sales (P/S) is 14% less than its last 4 quarters average of 3.6 and 12% less than its 5-year quarterly average of 3.5

Efficiency

How efficient is Gilead Sciences business performance
GILD's return on assets is up by 25% year-on-year but it is down by 3.2% since the previous quarter
Gilead Sciences's ROIC has increased by 23% YoY but it has decreased by 4.5% from the previous quarter
The company's return on equity rose by 17% YoY but it fell by 5% QoQ
GILD's return on sales is up by 17% year-on-year but it is down by 3% since the previous quarter

Dividends

What is GILD's dividend history
Dividend details
DPS
$3.02
Dividend yield
4.51%
Payout ratio
66.5%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 58% higher than its total liabilities
Gilead Sciences's current ratio has increased by 11% YoY and by 7% QoQ
The quick ratio has grown by 8% from the previous quarter and by 7% YoY
Gilead Sciences's debt is 9% higher than its equity
Gilead Sciences's equity has increased by 8% YoY and by 2.3% from the previous quarter
The company's debt to equity fell by 8% YoY and by 2.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.